CANTOS- Phase 3, randomized, double-blind, placebo controlled study of quarterly injections of canakinumab

The primary objective of this study is to demonstrate the superiority of at least one dose of canakinumab compared to placebo in reducing the risk of recurrent major cardiovascular disease events (cardiovascular death, non-fatal MI and stroke) in a population of clinically stable post-MI patients with elevated hsCRP receiving standard of care.

Heart & Vascular - Pharma Clinical Trials
Paul Huang, MD

Inclusion criteria:

  • 18 years of age or older

  • Males or Females who are no longer able to get pregnant

  • History of having a heart attack

Exclusion criteria:

  • History of significant kidney disease

  • History of tuberculosis

  • Currently taking any biologic drugs that target your immune system

  • History of HIV

  • History of Hepatitis B or C

Pharma Clinical Trials
Swedish Heart and Vascular Research